Solutions - Page 11

The company expects sales in the second half of the year to outpace those from the first and reiterated its annual revenue guidance, projecting growth between 20% and 21% for all of

Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than $650 million through 2030 as it taps domestic contractors to produce newly approved Nemluvio and

Cambrex revealed plans to spend $120 million to expand its Iowa manufacturing operations on the heels of a report last month that its owner was seeking a sale.

Nephron Pharmaceuticals’ manufacturing facility in West Columbia, South Carolina, is still running afoul of the FDA. In its most recent Form 483 report, the agency has cited several problems that were evident

Merck KGaA plans to discontinue operations at its production plant in Arklow, Ireland, “by the end of 2028,” a company spokesperson confirmed to Fierce Pharma. The decision follows a strategic review of

Private equity firm Curewell Capital is aiming to close the gap in U.S. API production with a majority investment in specialty CDMO Wilmington PharmaTech.

ACG, a supplier for solid dose drug manufacturers, is pumping $200 million into what will be the India-based company’s first empty-capsule production facility in the U.S.

The investment is part of the New Jersey company’s plan to spend more than $70 billion on manufacturing, R&D and capital projects in the U.S. starting this year.

With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia treatment with a $445 million injection of funds. The investment will increase the capabilities of AZ’s

In addition to substantial spray drying capacity, new CDMO Codis says it’s also equipped to handle commercial-scale work on amorphous solid dispersions, particle engineering and finished dose manufacturing for pharma, consumer health